These are top 10 stocks traded on the Robinhood UK platform in July
Piper Sandler initiated coverage on Hinge Health Inc (: HNGE) Monday with an overweight rating and a price target of $41.00. The company, currently valued at $2.72 billion, has seen its stock decline 8.29% over the past week, though InvestingPro analysis indicates an overall "GOOD" financial health rating.
The research firm cited Hinge Health’s proprietary technology and sophisticated distribution strategy as key factors that could sustain double-digit revenue compound annual growth rate as the company continues to dominate the $94 billion U.S. musculoskeletal market. With a robust current ratio of 2.31 and impressive gross margins of 79.46%, the company demonstrates strong operational efficiency. (InvestingPro subscribers can access 6 additional key tips about HNGE’s financial position.)
Piper Sandler highlighted the company’s AI-powered automated musculoskeletal care, which democratizes access, reduces the need for pharmaceutical and surgical interventions, improves adherence, and delivers clinical outcomes with economic impact.
The firm noted studies indicating a 2.4x+ return on investment across commercial and Medicare populations, suggesting Hinge Health’s pricing and 80.0%+ gross margins are sustainable over time.
Piper Sandler also expressed confidence in potential operating leverage as Hinge Health scales beyond its current base of 2,250 clients and 20.0 million contracted lives as of December 31, 2024.
In other recent news, Hinge Health Inc has garnered attention from multiple investment firms with positive ratings and price targets. Morgan Stanley (NYSE:MS) initiated coverage with an overweight rating and a price target of $46.00, citing Hinge Health’s strong growth and strategic partnerships in the musculoskeletal (MSK) digital therapy market. RBC Capital Markets also began coverage with an outperform rating and a $45 price target, emphasizing the company’s market leadership and potential for margin expansion. KeyBanc Capital Markets offered an overweight rating with a $45.00 price target, noting the company’s leadership in the underserved MSK market and its growth potential through a utilization-based pricing model.
Stifel joined the positive sentiment with a buy rating and a $48.00 price target, highlighting Hinge Health’s virtual physical therapy platform and its potential to reduce healthcare costs. The firm noted the company’s expansion into fully-insured plans as a growth opportunity. Analysts from these firms have pointed out Hinge Health’s competitive advantages, including its proprietary technology and integration capabilities. Overall, these recent developments underscore Hinge Health’s strong position in the digital healthcare market and its potential for continued growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.